EW Strangle Strategy
EW (Edwards Lifesciences Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure.
EW (Edwards Lifesciences Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $52.27B, a trailing P/E of 48.11, a beta of 0.87 versus the broader market, a 52-week range of 72.3-92.46, average daily share volume of 5.2M, a public-listing history dating back to 2000, approximately 16K full-time employees. These structural characteristics shape how EW stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.87 places EW roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 48.11 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on EW?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current EW snapshot
As of June 29, 2026, spot at $91.28, ATM IV 23.70%, IV rank 13.94%, expected move 6.79%. The strangle on EW below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 53-day expiry.
Why this strangle structure on EW specifically: EW IV at 23.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a EW strangle, with a market-implied 1-standard-deviation move of approximately 6.79% (roughly $6.20 on the underlying). The 53-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EW expiries trade a higher absolute premium for lower per-day decay. Position sizing on EW should anchor to the underlying notional of $91.28 per share and to the trader's directional view on EW stock.
EW strangle setup
The EW strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EW near $91.28, the first option leg uses a $95.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EW chain at a 53-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EW shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $95.00 | $3.20 |
| Buy 1 | Put | $87.50 | $2.90 |
EW strangle risk and reward
- Net Premium / Debit
- -$610.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$610.00
- Breakeven(s)
- $81.40, $101.10
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
EW strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on EW. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$8,139.00 |
| $20.19 | -77.9% | +$6,120.86 |
| $40.37 | -55.8% | +$4,102.72 |
| $60.55 | -33.7% | +$2,084.58 |
| $80.74 | -11.6% | +$66.44 |
| $100.92 | +10.6% | -$18.30 |
| $121.10 | +32.7% | +$1,999.84 |
| $141.28 | +54.8% | +$4,017.98 |
| $161.46 | +76.9% | +$6,036.13 |
| $181.64 | +99.0% | +$8,054.27 |
When traders use strangle on EW
Strangles on EW are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EW chain.
EW thesis for this strangle
The market-implied 1-standard-deviation range for EW extends from approximately $85.08 on the downside to $97.48 on the upside. A EW long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current EW IV rank near 13.94% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EW at 23.70%. As a Healthcare name, EW options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EW-specific events.
EW strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EW positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EW alongside the broader basket even when EW-specific fundamentals are unchanged. Always rebuild the position from current EW chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on EW?
- A strangle on EW is the strangle strategy applied to EW (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With EW stock trading near $91.28, the strikes shown on this page are snapped to the nearest listed EW chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EW strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the EW strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 23.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$610.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EW strangle?
- The breakeven for the EW strangle priced on this page is roughly $81.40 and $101.10 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EW market-implied 1-standard-deviation expected move is approximately 6.79%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on EW?
- Strangles on EW are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EW chain.
- How does current EW implied volatility affect this strangle?
- EW ATM IV is at 23.70% with IV rank near 13.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.